v3.25.2
Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)
€ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2025
EUR (€)
$ / €
entity
Jun. 30, 2024
$ / €
Dec. 31, 2024
$ / €
May 09, 2025
$ / €
May 07, 2025
$ / €
General principles and statement of compliance          
Number of entities being consolidated | entity 2        
Exchange rate at the end of period 1.172 1.0705 1.0389    
Hepalys Pharma, Inc          
General principles and statement of compliance          
Proportion of ownership interest 15.00% 15.00% 15.00%    
Licensing and collaboration agreement with CTTQ          
General principles and statement of compliance          
Exchange rate at the end of period 1.125     1.125 1.172
Inventiva Inc.          
General principles and statement of compliance          
Percent of ownership interest 100.00%        
Non-controlling interest | € € 0